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Summary 
 
Parkinson’s disease (PD) is a fatal 
neurodegenerative disorder that affects 1 in 100 
individuals over the age of 60.  PD results from 
dopaminergic neuronal atrophy localized within the 
substantia nigra of the midbrain; the pathology 
consists of fibrillar inclusions, Lewy Bodies, within 
substantia nigral neurons.  The principal 
component of Lewy Bodies is the protein  α-
synuclein.  Though 90-95% of PD cases are 
sporadic, familial forms result from the missense 
mutations A30P, A53T, or E46K in the α-synuclein 
gene.  Little is known about the properties of the 
recently discovered E46K mutation.  We 
hypothesized that the E46K mutation alters the 
conformation of α-synuclein in a potentially toxic 
manner that results in increased α-synuclein 
misfolding and alters its plasma membrane 
localization.  Therefore, the purpose of this thesis 
was to characterize E46K in budding yeast 
(Saccharomyces cerevisiae).  To further compare 
all familial mutants, double and triple E46K 
isoforms were synthesized with A30P and A53T 
mutations and tagged with green fluorescent 
protein (GFP).  All familial mutants, and control GFP 
or parent vector pYES2 were expressed in several 
naturally occurring and commonly studied budding 
yeast haploid strains and a diploid strain.  Growth 
curves and viability assays of one haploid strain 
revealed E46K to be toxic.  Consequently, we 
wanted to determine if E46K toxicity was strain 
specific.  Identical growth and viability assays were 
performed on several other haploid strains.  
Interestingly, no E46K toxicity was observed in any 
of the strains except the opposite-mating type of 
the toxic strain.  Therefore, to test if E46K toxicity 
was ploidy-specific, these analyses were performed 
on the diploid strain formed by the mating of the 
two toxic strains.  Unexpectedly, E46K and E46K 
variations were not toxic in the nearly genetically 
identical diploid.  Thus, strain and ploidy 
differences between strains must account for this 
selective E46K toxicity.  GFP fluorescence live-cell 
microscopy revealed that α-synuclein membrane 
localization was correlated with toxicity.  Further 
study of the underlying mechanisms for E46K 
toxicity in yeast may provide insight into its role in 
neuronal toxicity and familial PD.  
 
Introduction 
 
The brain is the central entity that defines each 
individual and when damaged, their personality may be  
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altered beyond recognition. The localization of brain 
damage determines which functions and characteristics 
are lost.  Though external brain trauma and cancers are 
readily identifiable causes of damage, neurological 
degeneration resulting from the misfolding of proteins is 
not.  Neurodegenerative diseases manifest themselves 
within the brain or nervous system differently, but all 
result in the chronic depletion of nervous tissue (Purves 
et al., 2004).  As these neurons that provide 
fundamental characteristics such as cognition, memory, 
and movement die, bodily functions cease to occur and 
patients slowly waste away to death.  
Parkinson’s disease (PD) is the second most 
common fatal neurodegenerative disorder of the central 
nervous system.  It afflicts 1 in 100 individuals over the 
age of 60, of which 5 to 10% are diagnosed before the 
age of 40 (PD Foundation, 2006).  Though 90 to 95% of 
all cases are sporadic, early onset familial forms of PD 
occur in 5 to 10% of patients (PD Foundation, 2006).  
The disease has no cure, and patients are destined to 
die from motor initiation failure.  The principal 
symptoms of PD are resting tremor, postural deficits, 
rigidity, and bradykinesia (Purves et al., 2004).  In 
addition, psychological studies suggest that PD patients 
exhibit motor learning deficits (Heindel et al., 1989; 
Helmuth et al., 2000).  As the disease progresses, the 
intensity of each symptom increases until the patient is 
at a complete loss to initiate voluntary movements.   
Chronic increases in motor initiation deficits 
are the direct result of neuronal atrophy localized within 
the substantia nigra in the midbrain (Purves et al., 
2004; Figure 1).  This vital structure consists of a thin 
black strip (1-2 mm wide) of dopaminergic neurons 
pigmented with neuromelanin (Purves et al., 2004).  
They function as an integral part of the basal ganglia 
which, is a complex circuit responsible for initiating 
voluntary movements.  Through numerous inhibitory 
and excitatory synapses, the substantia nigra functions 
as an initiator of voluntary movements (Figure 2).   
 
 
 
 
Figure 1:  Parkinson’s Disease Pathology. Image A is a 
saggital section along the longitudinal fissure that shows the 
location of the substantia nigra in the human brain, which is 
enclosed by a red box.  Image B is of the substantia nigra from 
a normal human brain depicted from a horizontal section.  
Image C shows the substantia nigra in a PD brain.  In  
Midbrain 
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Figure 2:  The Basal Ganglia and Voluntary Movement. This depiction of the basal ganglia details the flow of stimuli through it resulting 
in motor initiation. The colored words and lines, and their assigned letters correspond to the exact location of their structures and synaptic 
targets in image I. The substantia nigra, image II, synapses on both the caudate nucleus, B, and putamen, C. This is indicated on image I 
by the red and blue lines. The caudate nucleus, B, and putamen, C, synapse on the globus pallidus, D. On image I, this is represented by 
the convergence of the blue and red lines on a single structure. The globus pallidus, D, synapses on the thalamus, E, which is indicated by 
the green arrow on image I. The thalamus, E, synapses on the motor cortex, F, which is located at the end of the green arrows in image I. 
Excitatory stimuli traveling up from the substantia nigra and through the basal ganglia result in activation of the globus pallidus, relieving the 
thalamus of tonic inhibition. Consequently, an excitatory stimulus is sent to the motor cortex and movement is initiated.  
 
the PD brain, there is a significant decrease in the 
number of substantia nigral neurons compared to the 
normal brain.  This can be seen by the decreased black 
pigmentation of the substantia nigra in C. When cells in 
the pars compacta region of the substantia nigra die, 
the cascade of inhibitory and excitatory synapses 
through the caudate nucleus, putamen, and globus 
pallidus fail to relieve the thalamus of tonic inhibition 
(Purves et al., 2004).  Consequently, the pre-motor and 
motor cortexes are not stimulated and movement is not 
initiated (Purves et al., 2004; Figure 2).  Interestingly, 
symptoms of PD are not always expressed until 60 to 
80% of substantia nigral neurons are dead (Lansbury et 
al., 2003; Purves et al., 2004). 
Upon autopsy, PD pathology consists of 
neurofibrillary inclusions, Lewy Bodies, within 
substantia nigral neurons.  The principal component of 
Lewy Bodies is the protein α-synuclein (Spillantini et al., 
1998).  This protein is expressed throughout the brain 
and exists in a natively unfolded state localized to the 
plasma membranes of pre-synaptic terminals (Purves 
et al., 2004).  α-synuclein aggregation is specific to the 
substantia nigra of PD patients, suggesting that other 
unique features of these neurons are involved (Purves 
et al., 2004).  Although α-synuclein is intimately related 
to the pathogenesis of PD, its function remains 
unknown. 
 
Cellular Basis of PD 
Though the exact cellular basis of PD has yet to be 
discovered, and the vast majority of cases are sporadic, 
genetic studies have linked autosomal dominant familial 
forms of PD to       α-synuclein mutations A30P (Kruger 
et al., 1998), A53T (Polymeropoulos et al., 1997), and 
recently E46K (Zarranz et al., 2004).  In addition, 
mutations in parkin (Kitada et al., 1998) and DJ-1 
(Leroy et al., 1998) are associated with adolescent 
forms of PD (Dawson et al., 2003).    DJ-1 and Parkin, 
an E3 ligase, function within the ubiquitin-proteasomal 
pathway. (Dawson et al., 2003).  The dysfunction of 
parkin or DJ-1 is thought to exacerbate the potentially 
toxic properties of mutant α-synuclein in addition to 
being capable of causing PD on their own (Dawson et 
al., 2003; Purves et al., 2004).  Proteins to be degraded 
in the proteasome are tagged with the molecule 
ubiquitin (Purves et al., 2004).  UCH-L1, which is 
involved in both addition (ligase) and removal 
(hydrolase) of ubiquitin to/from α-synuclein, is also 
implicated in autosomal dominant familial PD because 
the S18Y mutation reduces its hydrolase activity (Liu et 
al., 2002).  The loss of hydrolase function could account 
for fibrillar α-synuclein being poly-ubiquitinated 
(Stefanis et al., 2001).  Mutations within PINK1 (Valente 
et al., 2004) and LRRK2 (Funayama et al., 2002) are 
also capable of causing familial forms of PD.  Though 
several proteins can cause PD, α-synuclein remains 
the principal target of investigations because it is 
always misfolded in PD, unlike the other proteins, and 
forms the hallmark feature of the disease, Lewy Bodies.   
Several questions on PD remain 
unanswered; 1) Why is neuronal atrophy specific to the 
Substantia Nigra?  2) Are Lewy Bodeies the toxic or 
neuroprotective form of α-synuclein?        3) What are 
the characteristics of α-synuclein-E46K, and how do 
they compare to A30P and A53T?  This thesis will focus 
on the latter question by comparative evaluation of 
E46K characteristics and previously discovered familial 
mutants A30P and A53T within budding yeast 
(Saccharomyces cerevisiae). 
 
Characteristics of α-Synuclein 
α-synuclein is a small, 140 amino acid, 14 kDa, natively 
unfolded protein localized within the pre-synaptic 
terminal (Uversky et al., 2002).  It acquires an α-helical 
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 conformation, in vitro, when exposed to fluorinated 
alcohols, detergents, or vesicles/membranes (Weinreb 
et al., 1996; Davidson et al., 1998).  The amino acid 
sequence is divided into three regions based on 
significantly different secondary-structure 
characteristics.  The N-terminus is amphipathic and 
contains residues 1-60 along with seven imperfect 
repeats of XKTKEGVXXXX that are thought to resist 
aggregation (Kessler et al., 2003; Uversky et al., 2002).  
All familial PD mutants occur in this region.  Amino 
acids 61-95 form the hydrophobic core, and are 
involved in facilitating aggregation (Uversky et al., 
2002).  Specifically, a stretch of 12-uncharged amino 
acids within that hydrophobic domain are required for 
fibril formation (Giasson et al., 2001).  This result is 
supported by the finding that the introduction of various 
charged amino acids into the central region decreases 
the rate of fibril formation (Giasson et al., 2001).  β-
synuclein, an α-synuclein homologue, lacks an 
uncharged sequence at this locus and consequently, 
does not aggregate (Lee et al., 2001).  The C-terminus, 
residues 96-140, is hydrophilic and unfolded due to 
many proline residues (Uversky et al., 2002). 
Initial studies of PD were aimed at 
determining the function of α-synuclein.  The several 
11-amino acid repeats in α-synuclein resemble those of 
apolipoproteins thus, Davidson et al. hypothesized that 
α-synuclein bound to vesicular membranes (1998).  
Their in vitro results indicated that α-synuclein bound to 
20 to 25 nm vesicles composed of acidic phospholipids.  
Furthermore, α-synuclein conformationally stabilized 
into an α-helix rich structure upon membrane binding 
(Davidson et al., 1998).  When analyzing the α-
synuclein familial PD mutants, A53T slightly decreases 
membrane binding affinity while A30P decreases it 
significantly compared to WT (Jensen et al., 1998; 
Perrin et al., 2000).  Detailed analysis of α-synuclein 
membrane binding properties shows that the N-
terminus binds and becomes α-helical while the C-
terminus remains unfolded in the cytoplasm (Perrin et 
al., 2000; Eliezer et al., 2001).  These secondary 
structural and binding characteristics, and the finding 
that the C-terminus is free to interact and conform to a 
variety a substrates, suggests that α-synuclein is 
involved in vesicular trafficking (Perrin et al., 2000; 
Eliezer et al., 2001). 
 Focusing on interactions between single α-
synuclein molecules, Conway and colleagues were the 
first to detail the process of monomeric α-synuclein 
conversion into fibrils (1998).  Specifically, they tested 
the hypothesis that familial PD results from acceleration 
of fibril formation by A30P and A53T.  This was 
accomplished by comparing the rates of fibril formation 
between A30P, A53T, and WT, in vitro (Conway et al., 
1998).  Familial mutants A53T and A30P aggregated 
into fibrils faster than WT, with A53T as the fastest 
overall (Conway et al., 1998).  This study provided the 
first evidence for A30P and A53T familial mutants 
causing PD by accelerating the rate of fibril formation.   
 Subsequent research by Conway et al. 
further characterized the monomer to fibril transition by 
determining the rate of monomeric α-synuclein 
consumption relative to the rate of fibril formation 
(2000).  Interestingly, the increased rate of monomeric 
A30P and A53T consumption did not account for their 
respective rates of fibril formation (Conway et al., 
2000).  As a result, they proposed that a protofibrillar 
intermediate must exist between monomeric and fibrillar 
α-synuclein conformations.  The existence of 
protofibrils was confirmed when they were separated 
from monomeric and fibrillar α-synuclein using gel-
filtration chromatography, and visualized with atomic 
force microscopy (AFM; Conway et al., 2000).  The 
AFM images revealed that protofibrils exist in one of 
two states: chains or rings of spheres (Conway et al., 
2000).  Significantly, protofibrils were observed to bind 
and form pores in synthetic and mouse brain-derived 
membranes similar to the β-barrel pores formed by 
bacterial toxins (Volles et al., 2001; Ding et al., 2002).  
Thus, Lewy Bodies may actually be the neuroprotective 
form of         α-synuclein if protofibrils are the toxic 
species because fibril formation consumes the 
oligomeric intermediates (Volles et al., 2001; Ding et al., 
2002; Figure 3). 
 
Neurodegeneration is Specific to the Substantia Nigra 
α-synuclein is expressed throughout the brain and yet, 
aggregation and neuronal atrophy occurs only in the 
substantia nigra of the PD brain (Purves et al., 2004).  
The reason for this pathological specificity remains 
unknown.  However, an oxidized form of dopamine (L-
dopa) binds and stabilizes protofibrils in vitro (Conway 
et al., 2001).  If protofibrils are the toxic agent in PD, 
then L-dopa would prolong the duration that α-
synuclein is in this toxic conformation (Conway et al., 
2001).  Unlike the vast majority of neurons in the brain, 
the neurotransmitter of the substantia nigra is 
dopamine.  Thus, oxidation of dopamine in the 
presence of protofibrils within substantia nigral neurons 
may rationalize PD specificity to this structure (Conway 
et al., 2001). 
 
Model Organisms 
In addition to primary neuronal cultures, several model 
organisms exist for the study of PD.  A line of 
transgenic mice overexpressing human α-synuclein 
was established and found to exhibit the PD 
characteristics of substantia nigral atrophy, motor 
initiation deficits, and intraneuronal aggregates (Masliah 
et al., 2000).  Interestingly, these aggregates are non-
fibrillar and less organized in contrast to the highly 
organized fibrils in PD (Goldberg and Lansbury, 2000).  
Drosophila transgenic for human α-synuclein and 
familial mutants A30P and A53T are also an 
established PD model (Feany and Bender, 2000).  
Drosophila expressing human α-synuclein exhibit 
features characteristic of PD including dopaminergic 
neuronal atrophy, motor deficits such as irregular flying, 
and intraneuronal aggregates (Feany and Bender, 
2000).  Interestingly, a line of mice expressing both 
human α and β-synucleins have a decrease in Lewy 
Body concentration and do not manifest PD symptoms 
(Hashimoto et al., 2001).  Together, these organisms 
serve as models that adequately represent the 
pathological and behavioral components of PD 
observed in humans (Lansbury et al., 2003). 
Our lab uses a Saccharomyces cerevisiae 
model that was recently established as a powerful 
means for the study of PD (Sharma et al., 2006).  The 
power of the yeast model is seen through several 
characteristics of the organism.  First, the yeast 
genome is completely sequenced, allowing for detailed 
mapping of yeast genes.  Second, rapid turnover of 
generations allows for a genetically based disease 
study over several generations in a number of days.  
Third, gene deletion, introduction, or overexpression 
can be performed in a few days with relative ease.    
 
  
 
Figure 3: α-Synuclein Aggregation and the Toxic Protofibril Hypothesis.  
The toxic Parkinson’s disease (PD) causing conformation of α-synuclein is unknown but toxic protofibrillar intermediates are gaining 
support as the causative agent.  WT-α-synuclein and familial mutants A30P, A53T, and E46K aggregate to form fibrils, Lewy Bodies, that 
are present in the substantia nigra of all PD brains.  Within the pathway toward aggregation, WT, A30P, and A53T form a protofibrillar 
intermediate between the monomeric and fibrillar states.  This pathway is not understood for E46K and the existence of an intermediate is 
not known.   
 
 
Fourth, the Yeast Genome Project, as well as various  
corporations, have synthesized thousands of different 
genetic knock-out strains that are readily available to 
the scientific community (Outeiro et al., 2004).   
Prior to my research, three yeast models 
existed for the study of PD or similar neurodegenerative 
disorders (Outeiro et al., 2003; Dixon et al., 2005; 
Zabrocki et al., 2005).  In addition to these, our lab has 
established a budding yeast, Saccharomyces 
cerevisiae, model that expresses human α-synuclein-
A30P, A53T, and A30P/A53T (Sharma et al., 2006).  
When WT, A30P, A53T, or A30P/A53T are expressed 
in the wild-type yeast strains BY4741, BY4743, and 
TSY623, no growth impairment is observed (Sharma et 
al., 2006).   
Fluorescence microscopy and GFP tags used 
to study α-synuclein intracellular properties when 
expressed in BY4741, BY4743, and TSY623 revealed 
three general phenotypes of  α-synuclein expression: 1) 
Cytoplasmically diffuse, 2) Plasma membrane or 
vacuolar localized, or 3) Aggregated (Sharma et al., 
2006).  Both A53T and WT forms of α-synuclein 
localize to the plasma membrane and form intracellular 
inclusions (Sharma et al., 2006).  α-synuclein-A30P is 
observed to be cytoplasmically diffuse while the double 
mutant, A30P/A53T, exists as either cytoplasmically 
diffuse or localized to the plasma membrane (Sharma 
et al., 2006).  In addition, these experiments 
demonstrate that no difference exists between α-
synuclein phenotypes in haploid, BY4741 and TSY623, 
or diploid, BY4743, strains (Sharma et al., 2006).  
Several other studies found similar results when one 
copy of α-synuclein is expressed but, two-copy 
expression is observed to be toxic to yeast except 
A30P (Outeiro et al., 2003; Dixon et al., 2005; Zabrocki 
et al., 2005).   
 
Summary of α-Synuclein Studies in Budding Yeast  
Numerous detailed growth analyses of α-synuclein-
A53T expression in budding yeast found that it was 
toxic at elevated expression levels and/or when cells 
had mutant proteasomes, and was capable of causing 
proteasomal dysfunction (Outeiro et al., 2003; Dixon et 
al., 2005; Zabrocki et al., 2005; Sharma et al., 2006).  
The hypothesis that toxicity is the result of impairment 
of α-synuclein degradation is further supported by the 
finding that when fibrillized, a significant portion of the 
protein is tagged with ubiquitin (Outeiro et al., 2003).  In 
addition, A53T and WT plasma membrane localization 
may result from traffic through the ER-Golgi secretory 
pathway (Dixon et al., 2005).  In contrast to A53T, A30P 
is not toxic at two copy or slightly elevated expression 
levels, and does not appear to pass through the 
secretory pathway (Outeiro et al., 2003; Dixon et al., 
2005).  Similarly, both A30P and A53T inhibit the ability 
of the proteasome to degrade other cellular proteins 
(Outeiro et al., 2003).  Though few studies of 
A30P/A53T in yeast have been performed, our lab 
shows it to be non-toxic at heterologous multi-copy 
expression levels and to display a phenotype between 
that of A30P and A53T (Sharma et al., 2006). 
 
Properties of Recently Discovered α-Synuclein-E46K 
In 2004, Zarranz et al. discovered a new autosomal 
dominant familial PD mutant,  α-synuclein-E46K, in a 
Spanish family.  Unlike A30P and A53T, little 
knowledge exists of this novel mutation.  Of the four 
published studies on E46K, three have characterized its 
role in aggregation and lipid binding (Choi et al., 2004; 
Greenbaum et al., 2005; Pandey et al., 2006).  The 
fourth one examined the clinical manifestations of E46K 
and found patients to have abnormal sleep in addition 
to motor deficits (Zarranz et al., 2005). 
 Immediately following the discovery of E46K, 
Choi et al. conducted the first study of the mutation 
(2004).  They analyzed the effects of E46K on α-
synuclein phospholipid binding, in vitro, and compared 
them to A30P and A53T.  Each mutant and WT were 
incubated with liposomes that resemble the membranes 
of synaptic vesicles to measure the absolute binding of 
α-synuclein to the membranes.  Compared to WT, 
E46K increased lipid binding by 56%.  In contrast, A30P 
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 and A53T reduced binding by 56% and 9 to 12% 
respectively.  Furthermore, E46K increased the binding 
of α-synuclein to liposomes regardless of their size.  
Thus, E46K increases the binding affinity of α-synuclein 
for liposomes/membranes (Choi et al., 2004). 
 Both A30P and A53T are linked to an 
increase in fibril concentration, but A53T also 
accelerates the rate at which those fibrils are formed 
unlike A30P (Conway et al., 1998).  Similar to A53T, 
E46K also increases the rate of fibril formation (Choi et 
al., 2004; Greenbaum et al., 2005).  Two in vitro studies 
demonstrated that as α-synuclein concentration 
increases, E46K increases the rate of fibril formation 
compared to WT (Choi et al., 2004 and Greenbaum et 
al., 2005).   In addition, Pandey et al. evaluated E46K 
effects on aggregation, in vivo, using human 
catecholaminergic neuroblastoma cells (2006).  Their 
experiments revealed E46K to form larger and more 
concentrated fibrils compared to WT, A30P, and A53T 
(Pandey et al., 2006).  From these studies, it can be 
concluded that E46K confers a higher propensity for α-
synuclein aggregation than the other familial mutants 
(Choi et al., 2004; Greenbaum et al., 2005; Pandey et 
al., 2006). 
 
Hypotheses and Aims 
Hypothesis: The E46K mutation alters the conformation 
of a-synuclein in a potentially toxic manner that results 
in increased a-synuclein misfolding and alters its 
plasma membrane localization. 
Little is known about the novel α-synuclein-
E46K mutation, but previous research found it to 
increase α-synuclein aggregation both in vitro and in 
vivo, and increase lipid binding affinity in vitro. (Choi et 
al., 2004; Greenbaum et al., 2005; Pandey et al., 2006).  
Therefore, the purpose of this thesis was to 
characterize α-synuclein-E46K in budding yeast, 
Saccharomyces cerevisiae.  We hypothesized that the 
E46K mutation alters the conformation of α-synuclein in 
a potentially toxic manner that results in increased α-
synuclein misfolding and alters its plasma membrane 
localization.  Our first aim was to determine if E46K and 
E46K variations are toxic to yeast.  Secondly, we 
wanted to examine the effects of E46K on α-synuclein 
membrane localization and aggregation.  Our final aim 
was to evaluate the effects of E46K on α-synuclein 
expression.  To assess whether E46K effects are strain 
and/or ploidy-specific, these analyses were performed 
on several well studied haploid yeast strains, and a 
diploid strain.  We found E46K toxicity to exhibit both 
strain and ploidy-specific toxicity, and α-synuclein 
membrane localization to be correlated with toxicity.  
The results of this study will significantly contribute to 
the body of knowledge on this new mutation, and be the 
first analysis of E46K in yeast. 
 
Methods 
 
Yeast Strains:  The wild-type budding yeast strains 
BY4741, BY4742, BY4743, W303, and TSY623 were 
used (Open Biosystems). 
 
Vectors:  The pYES2.1/V5-His-TOPO DNA vector 
(Invitrogen) was used to express all forms of α-
synuclein and green fluorescent protein (GFP) in the 
yeast.  
 
α-Synuclein Variations:  Human α-synuclein wild-type, 
A30P, A30P/A53T, E46K, A30P/E46K, E46K/A53T, and 
A30P/E46K/A53T with C-terminus GFP tags in the 
pYES2.1/V5-His-TOPO plasmid were used.  
 
α-Synuclein Expression:  A tightly regulated galactose 
inducible promoter (GAL1) within the pYES2.1/V5-His-
TOPO plasmid was used to control α-synuclein and 
GFP expression.  Yeast were grown in either Synthetic 
Complete (SC)-Uracil raffinose (2%) or SC-Uracil 
glucose (2%) to allow growth but suppress α-synuclein 
expression.  To allow for expression, yeast were grown 
in either SC-Uracil raffinose (2%) or SC-Uracil glucose 
(2%) overnight, centrifuged at 2500 rpm at 4 °C for 5 
min, and then washed with water.  The glucose or 
raffinose-free culture was then used to inoculate a 
volume of SC-Uracil galactose (2%), resulting in α-
synuclein expression.  The galactose culture was then 
incubated at 30 °C and 200 rpm shaking.   
 
Site-Directed Mutagenesis:  α-synuclein mutant 
A30P/E46Kwas synthesized previously in our lab by 
Sina Vahedi.  The α-synuclein mutants E46K/A53T, 
A30P/E46K/A53T all with C-terminus GFP were 
synthesized using the Gene Taylor Site-Directed 
Mutagenesis System and Taq High Fidelity polymerase 
(Invitrogen; Figures 4 and 5).  Both the E46K forward 
and reverse primers bound within the α-synuclein gene 
in the pYES2.1/V5-His-TOPO plasmid at                                       
5’-ATGTAGGCTCCAAAAACAAGAAGGGAGTGGTGC-
3’ and                                                5’-
CTTGGTTTTGGAGCCTACATAGAGAACACC-3’ 
(Qiagen).  The gene was mutated using either an α-
synuclein-A30P, α-synuclein-A53T, or α-synuclein-
A30P/A53T template all with  C-terminus GFP tags in 
pYES2.1/V5-His-TOPO vectors.  Agarose gel 
electrophoresis of the DNA mutagenesis products 
revealed bands near 6000 base-pairs corresponding to 
those expected for α-synuclein with a GFP tag.  The 
initial DNA mutagenesis thermocycled product was 
transformed into One Shot MAX Efficiency DH5α-T1 
Competent Cells (Invitrogen).  The mutated plasmid 
was then isolated from those cells using the Qiagen 
Mini-Prep kit.  A portion of this DNA and α-synucelin-
E46K was sent to the University of Chicago Cancer 
Research Center DNA Sequencing Facility which 
confirmed the desired mutations (Figure 5). 
 
Transformation of Yeast Strains:  The yeast strains 
BY4741, BY4742, BY4743, TSY623, W303, MHY810, 
and MHY803 were transformed with one of the 
following α-synuclein mutants: A30P/E46K, 
E46K/A53T, and A30P/E46K/A53T all with C-terminus 
GFP tags in the pYES2.1/V5-His-TOPO vector (Table 
1).  The sequenced α-synuclein-E46K with C-terminus 
GFP plasmid was transformed into BY4741.  The 
A30P/A53T mutant with C-terminus GFP was 
transformed into W303.  Transformations were 
confirmed by whole-cell yeast polymerase chain 
reaction (PCR). 
 
Western Blotting:  Cells were grown in SC-Uracil 
raffinose (2%) overnight, centrifuged at 2500 rpm at 4 
°C for 5 min then washed with water.  They were then 
transferred to SC-Uracil galactose (2%) media.  In most 
cases, cells from an ongoing O.D. 600 nm growth 
analysis were counted at 24 hours after α-synuclein  
expression, and 2.5 x 107 of those cells were isolated 
though centrifugation at room temperature and 14,000 
rpm in order to make cell lysates.  The cells were lysed 
using small glass beads and electrophoresis
  
 
Figure 4:  E46K/A53T and A30P/E46K/A53T α-Synuclein Mutagenesis.   
A.   Thermocycled Mutagenesis Products:  Thermocycled mutagenesis DNA products on 1% agarose gels from the E46K/A53T 
and A30P/E46K/A53T mutagenesis reactions using the pYES2 parent plasmid with either α-synuclein-A53T or A30P/A53T 
genes as the template.  Gel I has two lanes with the E46K/A53T mutation at ~6000 bps on the High Mass ladder.  Gel II has 
three lanes with A30P/E46K/A53T and a second mutagenesis reaction product for E46K/A53T, with both below 9416 bps on the 
Hind III mass ladder.  In both gels the control reaction consisted of a mutation within the LacZ gene. 
B.   Transformation of E. coli:  Thermocycled products from A were transformed into E. coli and plated in two volumes on LB + 
ampicillin plates (selective media) in order to circularize the linear pYES2 plasmid.  The pYES2 plasmid contained an ampicillin 
resistance gene. 
C.   PCR Screening for Plasmid:  Clean sequencing results require plasmid obtained from a single ancestor.  Individual colonies 
from both E46K combination mutants were screened for the pYES2 plasmid using PCR and primers specific for α-synuclein 
with C-terminal GFP.  Isolated α-synuclein-pYES2 was run as a control for the triple mutant but not for the double.  All positive 
screens are indicated by black bands at ~6000 bps on 1% agarose gels. 
D.   Plasmid Isolation:  DNA must be isolated from the cell to sequence.  Colonies 3 and 4 from E46K/A53T and 4 and 5 from 
A30P/E46K/A53T that positively screened for the plasmid in C were grown in liquid LB + ampicillin.  The plasmid was then 
isolated to be sent for sequencing at the University of Chicago.  These are 1% agarose gels of the plasmid isolation product. 
 
solubilizing buffer (ESB), which was composed of 
numerous protease inhibitors and Sodium Dodecyl 
Sulfate (SDS) detergent.  The lysates were then stored 
at -20 °C.  Tris-glycine gels (Invitrogen) were used to 
separate the proteins within the cell lysates.  Protein 
mass was determined using 10 µL of See Blue mass 
ladder (Invitrogen).  From each cell lysate, 20 µL was 
transferred into the gel and electrophoresed at 130 V.  
Running buffer diluted to 1X, (29.0 g Tris-Base, 144.0 g 
Glycine, 10.0 g SDS, 1 L H2O, and pH 8.7) and 1X 
transfer buffer (18.2 g Tris-Base, 90.0 g Glycine, 500 
mL H2O, and pH 8.3) were used.  Protein was 
transferred to PVDF membranes using the Semi-Dry 
Transfer apparatus (Biorad).  Blotting was performed 
using primary and secondary Anti-V5/Alkaline 
Phophatase (Invitrogen) to bind to α-synuclein, and 
primary Anti-Phosphoglycerate Kinase (PGK) from the 
Western Breeze kit (Invitrogen).  Coomasie staining 
was done by electrophoresing cell lysates on a Tris-
Glycine gel (as described above) and then washing the 
gel in fixing solution with slight agitation for two hours.  
The fixing solution was removed and coomasie staining 
solution was added for one hour.  Fixing solution was 
then added for 5 min, removed, and replaced with de-
staining solution overnight.  The gel was then 
photographed and dried.     
 
Growth Curve Analysis:  Optical density at 600 nm 
wavelength was used to assess cell growth during α-
synuclein expression.  Cells were grown overnight in 5 
mL of SC-Uracil raffinose (2%) or SC-Uracil glucose 
(2%) at 30 °C and 200 rpm shaking.  Cultures were 
counted to determine cell density using a
  
 
Figure 5:  α-synuclein-E46K/A53T and A30P/E46K/A53T Mutagenesis DNA Product Sequences. 
The DNA sequence of the E46K/A53T mutagenesis product is shown in A.  The A53T mutation is shown in blue and the E46K mutation in 
red.  The A30P/E46K/A53T DNA sequence is shown in B, and the A30P mutation is in yellow, E46K in red, and A53T in blue.  No other 
mutations within the α-synuclein gene are present. 
 
hemocytometer, centrifuged at 2500 rpm for 5 min at 4 
°C, and washed with water.  A flask of 35 mL SC-Uracil 
galactose (2%) was inoculated to a cell density of 2.0 x 
106 cells/mL and incubated at 30 °C and 200 rpm 
shaking for 48 hours.  At 0, 3, 6, 12, 18, 24, 36, and 48 
hours of α-synuclein expression, 1 mL from each 
culture was pipetted into a cuvet in duplicate.  Each 
cuvet was then analyzed using a Hitachi U-2000 
spectrophotometer to determine culture density.  The 
readings from each time-point were averaged and 
plotted on a graph of absorbance versus time.   
 
Growth Analysis through Cell Spotting:  Cells were 
grown in SC-Uracil raffinose (2%) or  SC-Uracil glucose 
(2%) overnight.  The cell density of each culture was 
determined after which, they were centrifuged at 2500 
rpm and 4 °C for 5 min, and then washed with water.  
From each culture, 2.0 x 107 cells were removed and 
pelleted through centrifugation at room temperature and 
14,000 rpm, and then the pellets were re-suspended in 
1 mL of water.  Each culture of density 2.0 x 107 
cells/mL had 100 µL transferred to a 96-well microtiter 
plate.  These cells were then serially diluted 5-fold 
across the plate.  Using the multi-pronged frogger, a 
small volume   (< 5 uL) of culture contained on the tip of 
each prong was spotted onto three SC-Uracil galactose 
(2%) and three SC-Uracil glucose (2%) plates.  Each 
plate was then incubated at 30 °C for 36 to 48 hours 
after which, they were scanned or photographed and 
stored at 4 °C. 
 
Time-Course Microscopy:  In order to analyze α-
synuclein properties during expression, cultures from a 
concurrently running O.D. 600 nm growth analysis were 
microscopically imaged at 18, 24, 36, and 48 hours of 
α-synuclein expression.  All images were taken using a 
Nikon TE2000-U fluorescent microscope and 
Metamorph 6.0 software.  From the GFP, wild-type α-
synuclein, A30P, A53T, A30P/A53T, E46K,  
 
 
A30P/E46K, E46K/A53T, A30P/E46K/A53T cultures (all 
with C-terminus GFP tags), 1 mL was removed and 
centrifuged at room temperature and 14,000 rpm for 6 
min.  The media was poured off, and the pellet re-
suspended in the remaining media.  Then, 10 µL of 
each culture was pipetted onto a glass slide and 
covered with a number-1 cover slip.  At 18 and 24 hour 
time-points in BY4741, E46K, A30P/E46K, E46K/A53T, 
and A30P/E46K/A53T cultures were not as dense as 
the others.  In order to establish equal density for 
microscopy, a second 1 mL of culture from E46K and 
associated mutants was added to their respective 
pellets, centrifuged, and re-suspended.  Imaging was 
performed by obtaining both differential interference 
contrast (DIC) and fluorescence images of the same 
cells.  This procedure was repeated enough times as 
was needed to image more than 500 cells from each 
culture.  If less than 500 cells were counted, those 
cultures are indicated by *. 
 
Statistical Analyses:  Statistical significance was 
established using a T-Test comparing the means of 
pYES2 and E46K or E46K variations at 18 and 24 
hours of α-synuclein expression. 
 
Results 
 
α-Synuclein-E46K is Toxic to Haploid Strain BY4741 
Our first goal was to determine the effects of E46K 
expression on budding yeast growth, the α-synuclein 
mutants E46K, A30P/E46K, E46K/A53T, or 
A30P/E46K/A53T were expressed using a galactose-
inducible promoter in the wild-type haploid budding 
yeast strain BY4741.  This is one of the most commonly 
studied of all yeast strains and has a completely 
sequenced genome.  O.D. 600 nm growth analysis over 
a 48-hour α-synuclein expression time-course was 
performed (Figure 6-A).  The growths of cultures 
expressing E46K or E46K variations were compared  
 Construct                                         Expression Vector                   Strain  
      
E46K a-synuclein-GFP  pYES2  BY4741 
    
 BY4742 
    
 
 
A30P/E46K a-synuclein-GFP  pYES2  BY4741 
    
 BY4742 
    
 BY4743 
    
 TSY623 
    
 W303 
    
 MHY803 
    
 MHY810 
    
 
 
E46K/A53T a-synuclein-GFP pYES2  BY4741 
    
 BY4742 
    
 BY4743 
    
 TSY623 
    
 W303 
    
 MHY803 
    
 MHY810 
    
 
 
A30P/E46K/A53T a-synuclein-
GFP pYES2  BY4741 
    
 BY4742 
    
 BY4743 
    
 TSY623 
    
 W303 
    
 MHY803 
    
 MHY810 
    
 
 
Parent Plasmid  pYES2  BY4742 
    
 
 
GFP   pYES2  BY4742 
    
 
 
WT a-synuclein-GFP  pYES2  BY4742 
    
 
 
A30P a-synuclein-GFP  pYES2  BY4742 
    
 
 
A53T a-synuclein-GFP  pYES2  BY4742 
    
 
 
A30P/A53T a-synuclein-GFP pYES2  BY4742 
 
Table 1:  Transformed Saccharomyces cerevisiae Strains. Newly and previously synthesized α-synuclein DNA constructs within the 
pYES2 vector were transformed into Saccharomyces cerevisiae.  On the left is the DNA construct, pYES2 expression vector in the center, 
and the right column indicates the strain that was transformed with the DNA construct within the same row. 
 
with pYES2 and GFP controls, and WT, A30P, A53T, 
and A30P/A53T α-synuclein isoforms.  During the first 
10 hours of α-synuclein expression, no differences in 
growth were observed.  However, at 18 and 24 hours 
after induction E46K and E46K variations significantly 
impaired growth compared to pYES2 and GFP controls, 
WT, A30P, A53T, and A30P/A53T (P18hrs ≤ 0.00068, 
P24hrs ≤ 0.0016).  Though E46K and E46K variations 
were toxic, E46K was significantly more toxic than 
A30P/E46K, E46K/A53T, and A30P/E46K/A53T at 18 
and 24 hours in BY4741 (P18hrs ≤ 0.0096, P24hrs ≤ 
0.0085).  By 48 hours of α-synuclein expression, all 
 BY4741 cultures had returned to equal density.  We 
use “toxicity” to denote growth impairment. 
Cell spotting was used as a second means 
for assessing E46K and E46K variation BY4741 growth 
impairment.  Separate cultures containing pYES2 and 
GFP controls, and WT, A30P, A53T, A30P/A53T, 
E46K, and E46K variations were serially diluted 5 times 
and spotted, in equal volume, onto SC-Uracil galactose 
plates to induce α-synuclein expression and SC-Uracil 
glucose plates as a control (Figure 6-B).  Similar to 
O.D. 600 nm analysis, E46K and E46K variations were 
toxic to BY4741 compared to the other familial mutants 
and controls. 
 
Expression of α-Synuclein-E46K is Decreased in 
BY4741 
By 48 hours of α-synuclein expression in BY4741, 
E46K toxicity was no longer observed and all cultures 
had returned to equal density.  To determine the effects 
of E46K on    α-synuclein expression during toxicity, 
western analysis of BY4741 was conducted at 24 hours 
after α-synuclein induction using an α-synuclein 
specific V5 antibody, and Anti-PGK as a loading control 
(Figure 6-C).  α-Synuclein expression was similar for 
WT, A30P, A53T, and A30P/A53T.  In contrast, 
expression of E46K and E46K variations was 
decreased.  Interestingly, E46K expression was lower 
than the E46K variations.   
 
Toxicity is Correlated with Membrane Localization in 
BY4741 
Because in vitro studies found E46K to increase 
phospholipid binding, we wanted test if α-synuclein 
localizes to the plasma membrane in yeast (Choi et al., 
2004).  Live-cell intracellular localization of α-synuclein 
in BY4741 at 18, 24, 36, and 48 hours after induction 
was investigated using C-terminal GFP tagged α-
synuclein constructs and fluorescence microscopy 
(Figure 6-D).  At least 500 cells from control GFP, WT, 
A30P, A53T, and E46K cultures were quantified at 
these time-points for either 1) Diffuse fluorescence, 2) 
Plasma membrane localization, or 3) Aggregation.  At 
all time-points, GFP remained cytoplasmically diffuse 
with modest aggregation at 48 hours of expression.  
A30P was diffuse throughout the time course as well.  
In contrast, WT, A53T, and E46K were membrane 
bound. 
 
E46K is Not Toxic to Haploids TSY623 and W303  
In order to determine if E46K toxicity is strain-specific, 
O.D. 600 nm and cell spotting growth analyses were 
performed identical to those for BY4741 on the 
commonly employed and well studied haploid strains 
TSY623 and W303.  Both growth analyses revealed no 
signs of toxicity for any of the α-synuclein mutants and 
controls (Figure 7-A and B; Figure 8-A and B).  Western 
analysis using the α-synuclein specific V5 antibody and 
Anti-PGK as a loading control at 24 hours post α-
synuclein induction demonstrated equal expression 
between mutants and controls in W303 (Figure 8-C).  In 
TSY623, α-synuclein expression was decreased for 
GFP, A30P, A30P/E46K, E46K/A53T, and 
A30P/E46K/A53T (Figure 7-C).  Unexpectedly, a 
distinct band was visible in the pYES2 lane near 50 kDa 
on the ladder, slightly lower than the ~ 54 kDa observed 
for GFP tagged α-synuclein.  Repeated western 
analysis in TSY623 produced an identical result (data 
not shown). 
 
α-Synuclein Translocates to Intracellular Compartments 
in TSY623 
No toxicity was observed in TSY623 therefore, we 
wanted to compare the toxic and non-toxic α-synuclein 
phenotypes.  Analysis of α-synuclein intracellular 
localization was performed using live-cell GFP 
fluorescence microscopy at 18, 24, 36, and 48 hours 
after α-synuclein induction in TSY623.  At least 500 
cells per time-point were quantitatively analyzed for 
either  1) Diffuse fluorescence, 2) Plasma membrane 
localization, 3) Aggregation, or 4) Intracellular 
compartmental fluorescence (Figure 7-D).  At 18 hours 
of α-synuclein expression, GFP and A30P exhibited 
diffuse cytoplasmic fluorescence and WT, A53T, and 
E46K localized to the plasma membrane.  However, at 
24 hours post-induction membrane localization was 
nearly lost in WT, A53T, and E46K, and intracellular 
compartmental fluorescence was observed.  In all GFP 
and α-synuclein cultures, compartmental diffuse 
fluorescence became the predominant phenotype 
through 24, 36, and 48 hour time-points. 
 
Diploidy Abolishes Toxicity in BY4743 
BY4741 mates with the nearly genetically identical 
BY4742 to form diploid BY4743.  To investigate the 
effects diploidy on E46K toxicity, O.D. 600 nm and cell 
spotting growth analyses were performed on BY4743 
as described previously (Figure 9-A and B).  
Surprisingly, doubling of the genome eliminated any 
signs of toxicity in both OD. 600 nm and cell spotting 
growth assays.  However, western analysis at 24 hours 
post-induction did not reveal a uniform level of 
expression across all mutants and controls (Figure 9-
C).  Expression was reduced in A30P, A30P/A53T, 
E46K, A30P/E46K, and E46K/A53T compared to GFP, 
WT, A53T, and A30P/E46K/A53T. 
 
E46K Toxicity is Haploid-Specific 
Because E46K toxicity was observed in haploid 
BY4741 but not in the closely related diploid BY4743, 
identical growth and protein expression assays were 
performed on the BY4741 opposite mating-type 
BY4742 to determine if E46K toxicity is mating-type or 
ploidy-specific (Figure 10-A and B).  If E46K is toxic to 
BY4742 then toxicity is ploidy-specific.  However, if 
E46K is not toxic then toxicity is mating-type specific.   
Interestingly, growth curve and cell spotting analyses 
found A30P/E46K to be significantly toxic to BY4742 
(P18hrs = 0.00001,     P24hrs = 0.000004).   
 
Decreased Expression is Linked with Toxicity in 
BY4742 
To determine if reduced α-synuclein-E46K expression 
was characteristic of haploid cells resistant to E46K 
toxicity, western analysis of BY4742 was conducted at 
24 hours after  α-synuclein induction using V5 and PGK 
antibodies (Figure 10-C).  As in BY4741, BY4742 
exhibited a decrease in expression for the toxic 
A30P/E46K mutant, while all non-toxic mutants and 
controls were expressed consistently.   
 
Discussion 
 
The mechanism by which α-synuclein causes PD 
remains to be discovered.  However, many previous 
studies have begun to characterize α-synuclein, and 
suggest that protofibrillar intermediates rather than 
fibrils are the toxic agent (Conway et al., 2000; Ding et 
al., 2002; Volles et al., 2001; Lansbury et al., 2003).  
The toxic protofibril hypothesis is strongly supported by 
  
 
 
 
 
 
 
 
Figure 6:  E46K is Toxic to Haploid BY4741.   
A.  Growth Curve Analysis:  The growth curve for BY4741 during 48 hours of α-synuclein expression for WT, A30P, A53T, A30P/A53T, 
E46K, A30P/E46K, E46K/A53T, or A30P/E46K/A53T, and pYES2 and GFP controls is shown.  Culture density is indicated by absorbance 
on the y-axis and time after α-synuclein induction on the x-axis.  Significant growth impairment is observed for E46K, A30P/E46K, E46K 
A53T, and A30P/E46K/A53Tat 18 and 24 hours (P18hrs ≤ 0.00068, P24hrs ≤ 0.0016).  Though all E46K and E46K variations are toxic to 
BY4741, E46K is significantly more toxic at 18 and 24 hours than A30P/E46K, E46K/A53T, and A30P/E46K/A53T (P18hrs ≤ 0.0096, 
P24hrs ≤ 0.0085).  By 48 hours, all cultures had returned to equal density.  Each of the points on the curves represents the mean from 
three trials.  Standard Error of the Mean (S.E.M.) bars for a 95% confidence interval are given for each point. 
B.  Cell Spotting:  BY4741 cells were serially diluted and spotted onto both α-synuclein inducing and suppressing media to evaluate the 
effects of α-synuclein expression on growth .  The solid media plate with non-α-synuclein inducing SC-Uracil glucose media is on the left 
and α-synuclein inducing SC-Uracil galactose media on the right.  E46K and E46K variations are toxic when expressed, as indicated by the 
decrease in growth on SC-Uracil galactose media compared to the other familial mutants and controls. 
C. Protein Expression:  At 24 hours of α-synuclein expression, western analysis was performed.  Expression was quantified using an 
antibody specific for the V5 tag on α-synuclein.  α-synuclein bands are present at ~54 kDa.  There is a decrease in E46K, A30P/E46K, 
E46K/A53T, and A30P/E46K/A53T expression compared to WT, A30P, A53T, and A30P/A53T.  E46K expression is also less than 
A30P/E46K, E46K/A53T, and A30P/E46K/A53T.  An antibody for PGK was used as a loading control. 
  
 
 
D. Live Cell Microscopy and Quantification of Phenotypes:  All α-synuclein constructs were C-terminally tagged with GFP; GFP was 
also expressed alone as a control.  At 18, 24, 36, and 48 hours after α-synuclein induction, at least 500 cells were imaged for GFP 
fluorescence at 1000x magnification from GFP, WT, A30P, A53T, A30P/A53T, E46K, A30P/E46K, E46K/A53T, and A30P/E46K/A53T 
cultures.  At each time-point, the imaged cells from GFP, WT, A30P, A53T, and E46K cultures were quantified as having either 1) Diffuse 
Fluorescence (blue), 2) Aggregation (maroon), 3) Plasma Membrane Localization (yellow).  The proportion of the total number of cells 
exhibiting a particular fluorescence phenotype is plotted for each familial mutant or control at the designated time-points.  At all time-points, 
WT, A53T, and E46K were membrane localized while A30P and GFP remained diffuse in the cytoplasm. 
 
  
 
 
 
 
 
 
 
Figure 7:  Characterization of E46K in Haploid TSY623.   
A. Growth Curve Analysis:  The growth curve for TSY623 during 48 hours of α-synuclein expression for WT, A30P, A53T, A30P/A53T, 
E46K, A30P/E46K, E46K/A53T, or A30P/E46K/A53T, and pYES2 and GFP controls is shown. Culture density is indicated by absorbance 
on the y-axis and time after α-synuclein induction on the x-axis.  Each of the points on the curves represents the mean from three trials.  
Standard Error of the Mean (S.E.M.) bars for a 95% confidence interval are given for each point.  No growth impairment is observed. 
B.  Cell Spotting:  TSY623 cells were serially diluted and spotted onto both α-synuclein inducing and suppressing media to evaluate the 
effects of α-synuclein expression on growth.  The solid media plate with non-α-synuclein inducing SC-Uracil glucose media is on the left 
and α-synuclein inducing SC-Uracil galactose media on the right. There is no observable difference in growth between familial mutants and 
controls in inducing media.  
C.  Protein Expression:  At 24 hours of α-synuclein expression, western analysis was performed.  Expression was quantified using an 
antibody specific for the V5 tag on α-synuclein.  α-synuclein bands are present at ~54 kDa.  Reduced expression is observed for GFP, 
A30P, A30P/E46K, E46K/A53T, and A30P/E46K/A53T.  An antibody for PGK was used as a loading control. 
 
  
 
 
 
D.  Live Cell Microscopy and Quantification of Phenotypes:  All α-synuclein constructs were C-terminally tagged with GFP; GFP was 
also expressed alone as a control.  At 18, 24, 36, and 48 hours after α-synuclein induction, at least 500 cells were imaged for GFP 
fluorescence at 1000x magnification from GFP, WT, A30P, A53T, A30P/A53T, E46K, A30P/E46K, E46K/A53T, or A30P/E46K/A53T 
cultures.  At each time-point, the imaged cells from GFP, WT, A30P, A53T, and E46K cultures were quantified as having either 1) Diffuse 
Fluorescence (blue),    2) Aggregation (maroon), 3) Plasma Membrane Localization (yellow), 4) Vacuolar Fluorescence (light blue).  The 
proportion of the total number of cells exhibiting a particular fluorescence phenotype is plotted for each familial mutant or control at the 
designated time-points.  At 18 hours, WT, A53T, and E46K were membrane localized while A30P and GFP remained diffuse in the 
cytoplasm.  Over time, membrane localization is lost for WT, A53T, and E46K, and all familial mutants and GFP predominantly exhibited 
vacuolar fluorescence by 24 hours. 
 
  
 
Figure 8:  Characterization of E46K in Haploid W303.   
A.  Growth Curve Analysis:  The growth curve for W303 during 48 hours of α-synuclein expression for WT, A30P, A53T, A30P/A53T, 
E46K, A30P/E46K, E46K/A53T, or A30P/E46K/A53T, and pYES2 and GFP controls is shown. Culture density is indicated by absorbance 
on the y-axis and time after α-synuclein induction on the x-axis.  Each of the points on the curves represents the mean from three trials.  
Standard Error of the Mean (S.E.M.) bars for a 95% confidence interval are given for each point.  No toxicity is observed. 
B.  Cell Spotting:  W303 cells were serially diluted and spotted onto both α-synuclein inducing and suppressing media to evaluate the 
effects of α-synuclein expression on growth.  The solid media plate with non-α-synuclein inducing SC-Uracil glucose media is on the left 
and α-synuclein inducing SC-Uracil galactose media on the right. There is no observable difference in growth between familial mutants and 
controls in inducing media.  
C.  Protein Expression:  At 24 hours of α-synuclein expression, western analysis was performed.  Expression was obtained using an 
antibody specific for the V5 tag on α-synuclein.  α-synuclein bands are present at ~54 kDa.  Expression is consistent for familial mutants 
and controls.  An antibody for PGK was used as a loading control. 
  
 
 
Figure 9:  E46K is not toxic in Diploid BY4743.   
A.  Growth Curve Analysis:  The growth curve for BY4743 during 48 hours of α-synuclein expression for WT, A30P, A53T, A30P/A53T, 
E46K, A30P/E46K, E46K/A53T, or A30P/E46K/A53T, and pYES2 and GFP controls is shown. Culture density is indicated by absorbance 
on the y-axis and time after α-synuclein induction on the x-axis.  Each of the points on the curves represents the mean from three trials.  
Standard Error of the Mean (S.E.M.) bars for a 95% confidence interval are given for each point.  No toxicity is observed. 
B. Cell Spotting:  BY4743 cells were serially diluted and spotted onto both α-synuclein inducing and suppressing media to evaluate the 
effects of α-synuclein expression on growth.  The solid media plate with non-α-synuclein inducing SC-Uracil glucose media is on the left 
and α-synuclein inducing SC-Uracil galactose media on the right. There is no observable difference in growth between familial mutants and 
controls in inducing media.  
C.   Protein Expression:  At 24 hours of α-synuclein expression, western analysis was performed.  Expression was obtained using an 
antibody specific for the V5 tag on α-synuclein.  α-synuclein bands are present at ~54 kDa.  Reduced expression is observed for A30P, 
A30P/A53T, E46K, A30P/E46K, and E46K/A53T compared to GFP, WT, A53T, and A30P/E46K/A53T.  An antibody for PGK was used as a 
loading control. 
  
 
 
Figure 10:  E46K is Required for Toxicity in Haploid BY4742.   
A.  Growth Curve Analysis:  The growth curve for BY4742 during 48 hours of α-synuclein expression for WT, A30P, A53T, A30P/A53T, 
E46K, A30P/E46K, E46K/A53T, or A30P/E46K/A53T, and pYES2 and GFP controls is shown.  Culture density is indicated by absorbance 
on the y-axis and time after α-synuclein induction on the x-axis.  Each of the points on the curves represents the mean from three trials.  
A30P/E46K is significantly toxic at 18 and 24 hour of α-synuclein expression (P18hrs = 0.00001, P24hrs = 0.000004).  Standard Error of 
the Mean (S.E.M.) bars for a 95% confidence interval are given for each point.  
B.  Cell Spotting:  BY4742 cells were serially diluted and spotted onto both α-synuclein inducing and suppressing media to evaluate the 
effects of α-synuclein expression on growth.  The solid media plate with non-α-synuclein inducing SC-Uracil glucose media is on the left 
and α-synuclein inducing SC-Uracil galactose media on the right.  A30P/E46K is toxic when expressed, as indicated by the decrease in 
growth on SC-Uracil galactose media compared to the other familial mutants and controls.  
C. Protein Expression: At 24 hours of α-synuclein expression, western analysis was performed.  Expression was obtained using an 
antibody specific for the V5 tag on α-synuclein.  α-synuclein bands are present at ~54 kDa.  There is a decrease in A30P/E46K expression 
compared to the other familial mutants and controls.  An antibody for PGK was used as a loading control.
 
 the finding that protofibril formation remains the only 
similarity between the A30P and A53T familial mutants, 
and protofibrils bind and form pores in synthetic and 
mouse brain-derived membranes similar to those of 
bacteria toxins (Conway et al., 2000; Ding et al., 2002; 
Volles et al., 2001).  Whether protofibrils exist within the 
E46K fibrillization pathway is unknown.  The only 
known characteristics of this new mutant are that it 
increases α-synuclein aggregation both in vitro and in 
vivo relative to WT, and increases lipid binding in vitro 
compared to A30P, A53T, and WT (Choi et al., 2004; 
Greenbaum et al., 2005; Pandey et al., 2006).  
In the present study, our budding yeast 
model was employed to characterize E46K in the 
commonly studied and naturally occurring haploid 
strains BY4741, BY4742, TSY623, and W303, and 
diploid strain BY4743 (Sharma et al., 2006).  
Specifically, we had three major aims: 1) Determine if 
E46K and E46K variations are toxic to yeast, 2) 
Examine the effects of E46K on α-synuclein membrane 
localization and aggregation, and 3) Evaluate the 
effects of E46K on α-synuclein expression.  We 
hypothesized that the E46K mutation alters the 
conformation of α-synuclein in a potentially toxic 
manner that results in increased α-synuclein misfolding 
and alters its plasma membrane localization.  To 
assess whether E46K effects are strain and/or ploidy-
specific, these analyses were performed on several well 
studied haploid yeast strains, and a diploid strain. 
 
E46K Toxicity is Strain and Ploidy-Specific 
Our first finding was that E46K toxicity is specific to the 
naturally occurring and well studied haploids BY4741 
and BY4742.  There is little genetic variation between 
these two strains which, suggests that toxicity in one 
should be expected in the other.  Our finding that only 
A30P/E46K is toxic to BY4742 indicates that the toxic 
species is not merely E46K itself, but rather that E46K 
must be present in order to induce toxicity.  This, 
therefore, links E46K toxicity between BY4741 and 
BY4742.  Because several other common haploid 
strains and diploid BY4743 were evaluated in an 
identical manner and no toxicity was observed, we can 
first conclude that toxicity is strain-specific.   
The finding of strain-specific toxicity raises 
the important issue of rationalizing this observation.  
Due to the lack of E46K research, and the complete 
absence of it in yeast models, there is an array of 
possibilities, two of which will be introduced.  Based on 
GFP fluorescence microscopy observations of α-
synuclein in BY4741 and TSY623, it is feasible that 
each stain has a means for managing the expression of 
E46K.  In TSY623, vacuolar isolation may prevent      α-
synuclein from performing toxic functions or inhibiting 
vital ones.  Since these results do not implicate a 
similar mechanism in BY4741, the failure to degrade or 
isolate α-synuclein may be a cause of toxicity.  A 
second possible explanation rests on the subtle genetic 
differences between strains.  Perhaps the presence of 
chaperone, suppressor, or a variety of other enzymes 
integral to controlling cellular proteins differs between 
strains, and certain strain-specific proteins confer 
resistance to E46K toxicity.   
 E46K toxicity was not merely strain-specific 
but also haploid-specific.  Thus, the genomic dosage 
affects the presence of toxicity.  The BY4741, BY4742, 
and BY4743 evaluations provided evidence for the 
presence of toxicity-suppressing proteins that are not 
completely effective at single-copy expression levels.  
However, at two-copy expression levels suppressor or 
regulatory proteins may be in high enough 
concentration to keep the cell below a toxic threshold 
concentration of α-synuclein. 
In common between BY4741 and BY4742 is 
that the presence of E46K is required for toxicity thus, 
implying that the E46K mutation itself alters the 
conformation of α-synuclein in a toxicity inducing 
manner.  If true, then why would E46K alone not be 
toxic in BY4742?  The BY4741 and BY4742 genotypes 
are nearly identical but the cellular and cytoplasmic 
environments are certainly not. For example, there are 
differences in cell volume and expression levels of 
cellular proteins.  The environment in which α-
synuclein-E46K folds may lead to the protein acquiring 
different stable confirmations in each strain but 
A30P/E46K in BY4742 and E46K in BY4741 are most 
similar.  Therefore, we conclude that haploid specificity 
is likely due to the expression levels of specific 
suppressor or regulatory proteins that are present in 
BY4741, BY4742, and BY4743. 
 
E46K Exhibits Strain-Specific Cellular Distribution 
Our second finding was that quantitative live-cell GFP 
fluorescence microscopy of α-synuclein intracellular 
localization performed on haploid strain BY4741 
produced results for GFP, WT, A30P, and A53T that 
are in agreement with those previously published by our 
lab (Sharma et al., 2006).  No quantitative analysis of 
phenotypes was provided for the BY4741 portion of that 
previous study.  This research establishes the first 
quantitative evidence for E46K membrane localization 
in BY4741 and budding yeast.  Though there are no 
budding yeast models to compare this finding to, it does 
support the Choi et al. conclusion that E46K increases 
α-synuclein phospholipid binding affinity (2004).  In 
contrast to our previously published data on TSY623, 
membrane localization for WT, A53T, and E46K is lost 
by 24 hours of α-synuclein expression, and 
intracompartmental fluorescence in what appears to be 
the vacuole predominates through 48 hours based on 
D.I.C. images.  At no point in the BY4741 or TSY623 
time-courses were aggregates the predominant 
phenotype in any familial mutants or controls.  By 48 
hours post-induction, modest aggregation was 
observed in many of the BY4741 cultures including 
GFP which, may be attributed to the accumulation of 
foreign protein after a long period of expression if not 
degraded.   E46K aggregation was expected based on 
the Greenbaum et al. (2005) and Pandey et al. (2006) 
findings that E46K increases the propensity for α-
synuclein to aggregate.  
 
E46K Toxicity is Dependent on Membrane Localization, 
Not Aggregation 
Lastly, we found that critical analysis of the relationship 
between the fluorescence phenotypes and E46K or 
E46K variation toxicity in BY4741 leads us to conclude 
that toxicity is dependent on membrane localization, not 
aggregation.  In TSY623, membrane localization is lost 
and no toxicity is observed.  Based on the toxic 
protofibrillar hypothesis presented in the introduction, it 
is plausible that a membrane binding oligomeric α-
synuclein species confers toxicity.  Though this 
research provides no direct evidence of protofibrillar 
existence, the absence of visible aggregates during 
toxicity but presence of E46K membrane localization 
implies their involvement.  Furthermore, membrane 
localization correlating with toxicity is also supported by 
  
 
Figure 11:   Does E46K Form Toxic Protofibrils in Yeast? 
The transition of  α-synuclein-E46K from monomer to fibril is depicted with the possible formation of protofibrils in red.  In the monomeric α-
synuclein lane, E46K is localized to the plasma membrane at 18 hours of α-synuclein expression , and within the vacuole at 24 hours in 
TSY623.  No toxicity is observed with the perivacuolar phenotype in TSY623, and vacuolar localization may degrade the toxic α-synuclein 
species.  The fibril lane shows the presence of E46K aggregates (red arrows) at 48 hours of α-synuclein expression in BY4741.  No toxicity 
is observed with the fibrillar phenotype at this time-point in BY4741.  The protofibril lane demonstrates the possibility that toxic protofibrils 
form at 18 and 24 hours post-α-synuclein induction in BY4741 and membrane localize to cause toxicity.   
 
the Volles et al. (2001) and Ding et al. (2002) findings 
that protofibrils bind and form pores in synthetic 
membranes.  Perhaps, membrane bound α-synuclein in 
BY4741 contains protofibrils that alter membrane 
permeability in a deleterious manner (Volles et al., 
2001; Ding et al., 2002; Figure 11). 
 Membrane localization in WT, A53T, and 
E46K is lost in TSY623 by 24 hours of α-synuclein 
expression and no toxicity is observed.  Perivacuolar 
localization of α-synuclein may protect TSY623 from 
E46K toxicity.  Interestingly, Cuervo et al. demonstrated 
that A30P and A53T inhibited their own as well as other 
protein’s translocation into the mammalian lysosome 
(2004).  In budding yeast, the vacuole functions as an 
analogous structure to the lysosome, yet no such 
impairment is observed in TSY623.  This contrasting 
result may be the product of different protein 
involvement in facilitating translocation of α-synuclein 
into the vacuole compared to the lysosome of human 
PC12 cells.  Specifically, α-synuclein is transported into 
the lysosome of human cells by the chaperone protein 
hsp70 when it recognizes the VKKDQ amino acid 
sequence in α-synuclein (Cuervo et al., 2004).  In 
BY741, no such vacuolar chaperone may exist and 
therefore, those cells are unable to degrade the toxic α-
synuclein species via this mechanism while TSY623 
can. 
 
 
E46K Toxicity is Linked to Decreased α-Synuclein 
Expression 
E46K and E46K variations are significantly toxic to 
BY4741 at 18 and 24 hours after α-synuclein induction.  
In BY4742, A30P/E46K is toxic at these times as well.  
Because western analysis of α-synuclein at 24 hours 
post-induction demonstrated decreased expression of 
all toxic species in both BY4741 and BY4742, and that 
toxicity is lost by 48 hours post-induction, it is plausible 
that cells expressing α-synuclein the least were 
selected for and allowed to replicate.  Furthermore, 
E46K variations were significantly less toxic and slightly 
more expressed than E46K in BY4741 during toxicity.  
Thus, this serves as evidence for a scheme where α-
synuclein expression decreases as toxicity increases.  
Since only A30P/E46K is toxic to BY4742, the degree 
of toxicity relative to α-synuclein expression cannot be 
elaborated on.  These results from western analysis 
also imply that aggregation is not required for toxicity 
because E46K is expressed at such low concentration 
during the initial hours of induction that aggregates 
either do not form or are not observable.  In addition, if 
aggregates are only observed in replicating cells then 
those clusters of α-synuclein may be in an inactive or 
protective state.  
 In TSY623 and BY4743 no toxicity was 
observed even though there were numerous instances 
of decreased α-synuclein expression.  In TSY623 
specifically, decreased expression of A30P and 
A30P/A53T was consistent with that of Sharma et al. 
 (2006).  These findings potentially indicate that specific 
α-synuclein isoforms are toxic to BY4743 and TSY623 
but that toxicity occurs before log phase growth and the 
cells expressing the deleterious isoform the least are 
selected for shortly after induction.  A second possible 
explanation is that diploid BY4743 expresses proteins 
capable of degrading α-synuclein or suppressing its 
transcription in high enough concentration to quickly 
lower the cytoplasmic concentration of any toxic 
species.  In TSY623, similar or analogous proteins 
expressed at single-copy levels are sufficient to lower 
the concentration of any toxic α-synuclein species 
below a certain threshold.  Based on this logic, α-
synuclein mutants with low expression may be toxic in 
those strains without altering the growth curves.  
 
Inconsistencies 
There are five prominent inconsistencies that remain to 
be accounted.  First, and most importantly, the growth 
impairment during log phase in BY4741 yeast 
expressing E46K or E46K variations, and A30P/E46K in 
TSY623 is referred to as toxicity because log-phase 
growth is impaired.  Toxicity is not used in a sense that 
implies the death of cells because a substance can be 
toxic without causing death.  This research does not 
provide data indicating whether the cells are actually 
dying during toxicity or if they are growing at a slower 
rate.  Second, our lab previously demonstrated that α-
synuclein-WT and A53T localize to the plasma 
membrane in TSY623 at 24 hours after induction 
(Sharma et al., 2006).  Our current results demonstrate 
that membrane localization is lost by 24 hours after 
induction in TSY623.  If a time-course analysis were 
performed in the Sharma et al. study, it would allow for 
a more thorough and relevant comparison but the lack 
thereof warrants no further elaboration on the matter 
(2006).  Third, A30P/E46K exhibited a slight decrease 
in growth in BY4742 on non-inducing SC-Uracil glucose 
media compared to the other mutants and controls.  
This cell spotting experiment was repeated several 
times, all producing similar results.  A sporadic mutation 
within the pYES2 vector, such as one within the uracil 
synthesis gene, could reduce the ability of A30P/E46K 
to grow in non-inducing media that is depleted of uracil.  
Consequently, A30P/E46K toxicity may be slightly 
exaggerated on the growth curve and cell spotting 
assays.  Fourth, significant growth impairment is 
observed in W303 for pYES2 (P18hrs = 0.01).  This could 
have resulted from a cell-counting error and is not 
observed in the cell spotting assay.  Finally, a distinct 
band is visible within the pYES2 control lane on the 
TSY623 western blot that was probed with the α-
synuclein-specific V5 antibody.  This band is located at 
a lower molecular weight than the α-synuclein bands 
which, indicates that it may be the result of non-specific 
binding of the antibody.  This experiment was repeated 
and produced an identical result.  Re-transformation of 
TSY623 with pYES2 will need to be completed to 
provide a definitive explanation.   
 
Future Research 
This project will continue through August of 2008.  
Therefore, the future research to be discussed will 
actually be performed.  Our first aim is to determine the 
rate of E46K degradation through western analysis at 
several time-points during the loss of α-synuclein 
induction.  The degradation of α-synuclein is 
hypothesized to play a critical role in PD neuronal 
toxicity.  Secondly, the presence of apoptosis during 
toxicity will be investigated by staining them with 
dihydorrhodamine (DHR-1, 2, 3) to determine if cells 
are dying or simply growing slower than the controls 
and other familial mutants.  Third, oxidative stress is 
linked to PD and therefore, the effects of E46K on 
oxidative stress will be examined using the FUN stain.  
Lastly, our laboratory previously established the first 
fission yeast (Schizosaccharomyces pombe) model for 
PD, and we intend to characterize E46K within it 
(Brandis et al., 2006). 
 
Conclusion 
 
Recently discovered α-synuclein-E46K increases 
aggregation both in vivo and in vitro, and increases its 
membrane binding affinity (Choi et al., 2004; 
Greenbaum et al., 2005; Pandey et al., 2006).  In this 
study, we have characterized E46K in a variety of 
naturally occurring budding yeast strains.  We 
demonstrate that E46K exhibits both haploid and strain-
specific toxicity in yeast.  Furthermore, the presence of 
the E46K mutation is required for toxicity, and toxicity is 
abolished in a diploid nearly genetically identical to the 
haploids E46K is toxic to.  Toxicity is also linked with 
decreased α-synuclein expression.  Finally, toxicity is 
dependent on membrane localization and not 
aggregation.  This finding supports the toxic 
protofibrillar hypothesis.  As numerous studies of A30P 
and A53T have provided valuable insight into the 
biological basis of PD, E46K is sure to reveal many 
characteristics of α-synuclein and its pathological 
function.  This thesis has contributed a significant 
amount of cellular, molecular, and biochemical 
information to our understanding of the properties of 
E46K, and was the first to characterize it within yeast. 
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